Flash Finance

Indegene LimitedINDGNCorporate

Healthcare Research, Analytics & Technology Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹598.30
MCap ₹14,408 Cr · P/E 35.9
Indegene Limited — Stock analysis & AI research Indegene Limited — Seasonality — best & worst months Indegene Limited — Technical indicators & charts Indegene Limited — Technical setup — score, trend, support & resistance Indegene Limited — Ascending Channel pattern forming Indegene Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 Small Cap Stocks List 📈 Stocks Near 52-Week High📈 Bollinger Squeeze Stocks📈 Bullish EMA Alignment📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks ⚖️ vs Syngene International 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,063 Cr
Sales · Jun 2026
+39.7% YoY
₹174 Cr
Operating Profit · Jun 2026
+12.2% YoY
16.4%
OPM % · Jun 2026
-19.6% YoY
₹116 Cr
Net Profit · Jun 2026
-0.2% YoY
₹4.84
EPS · Jun 2026
-0.4% YoY

📝 Indegene Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Indegene Limited reported revenue of ₹1,063 crore for the quarter ended June 2026 (Q1 FY27), up 39.7% from ₹761 crore in the same quarter last year, and up 6.0% sequentially over the March 2026 quarter.

Net profit fell 0.2% year-on-year to ₹116 crore, from ₹116 crore. Earnings per share (EPS) came in at ₹4.84.

Operating profit stood at ₹174 crore — an operating margin (OPM) of 16.4%, compared with 20.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Indegene Limited posted revenue of ₹3,510 crore, a growth of 23.6% over FY25, with a net profit of ₹401 crore (down 1.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,812 crore with a net profit of ₹401 crore.

Valuation snapshot

At the current price of ₹598.30, INDGN has a market capitalisation of ₹14,408 crore and a trailing P/E of about 35.9.

Within the Healthcare Research, Analytics & Technology industry, it is the largest of the 10 companies we track by market value.

Shareholding pattern

As of Mar 2026, foreign institutional investors (FIIs) 10.27%, domestic institutional investors (DIIs) 8.29%, public shareholders 81.43% of Indegene Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹14,408 Cr
Current Price ?
₹598.3
P/E ?
35.91above ind
Industry P/E ?
35.60
P/B ?
4.59
P/S ?
3.78
P/FCF ?
23.77
Enterprise Value ?
₹14,552 Cr
EV/EBITDA ?
22.80
PEG ?
2.24
Earnings Yield ?
3.4%
Dividend Yield ?
0.33%
Profitability & Returns
Sales (TTM) ?
₹3,812 Cr
OPM ?
16.7%
Profit after tax (TTM) ?
₹401 Cr
EPS (TTM) ?
₹16.66
ROCE ?
19.0%
ROE ?
12.8%
ROA ?
8.7%
Growth
Sales — latest qtr ?
₹1,063 Cr
PAT — latest qtr ?
₹116 Cr
YoY qtr sales growth ?
39.7%
YoY qtr profit growth ?
-0.2%
Sales growth (3y) ?
15%
Sales growth (5y) ?
29%
Profit growth (3y) ?
16%
Profit growth (5y) ?
23%
Financial Health
Debt ?
₹144 Cr
Debt to Equity ?
0.05
Interest Coverage ?
25.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
Pledged percentage ?
N/A
Market
Return 3 months ?
17.1%
Return 6 months ?
22.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 6326086366736736766877207567618049421,0031,063 +39.7% +6.0%
Operating Profit 9797121149139129126132148155141160164174 +12.2% +6.2%
Other Income 132812132622213826222019-1029 +31.2% +390.0%
Interest 12131212121243344576 +73.0% -8.6%
Depreciation 2020201818201920212223404244 +104.2% +5.0%
Profit Before Tax 7992101132134120124146149152133135105153 +0.4% +45.4%
Net Profit 4968759995889211011811610210380116 -0.2% +45.2%
EPS 2.203.083.384.454.263.673.844.594.904.864.264.293.314.84 -0.4% +46.2%
OPM % 15.3% 16.0% 19.0% 22.1% 20.7% 19.1% 18.4% 18.3% 19.6% 20.4% 17.5% 16.9% 16.4% 16.4% -19.6% +0.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,839 Cr ₹3,510 Cr ₹3,812 Cr +23.6%
Operating Profit ₹535 Cr ₹619 Cr ₹638 Cr +15.8%
OPM % 18.84% 17.65% 16.74% -6.3%
NPM % 14.35% 11.44% 10.52% -20.3%
Other Income ₹107 Cr ₹51 Cr ₹58 Cr -52.2%
Depreciation ₹80 Cr ₹127 Cr ₹149 Cr +57.5%
Interest ₹22 Cr ₹19 Cr ₹22 Cr -14.0%
EBIT ₹454 Cr ₹493 Cr ₹489 Cr +8.4%
PBT ₹539 Cr ₹525 Cr ₹526 Cr -2.7%
Tax ₹69 Cr ₹98 Cr ₹99 Cr +42.8%
Net Profit ₹407 Cr ₹401 Cr ₹401 Cr -1.5%
EPS ₹17.00 ₹16.72 ₹16.70 -1.6%
Material Cost — — — —
Employee Cost ₹886 Cr ₹1,565 Cr ₹1,743 Cr +76.7%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 44444848 +0.0%
Reserves 1,0201,3852,5683,091 +20.4%
Borrowings 502490102144 +41.2%
Other Liabilities 6386276091,337 +119.5%
Total Liabilities 2,2042,5463,3264,620 +38.9%
Fixed Assets 6646466781,812 +167.3%
CWIP 00412 +200.0%
Investments 6147961,2901,100 -14.7%
Other Assets 9261,1031,3551,697 +25.2%
Total Assets 2,2042,5463,3264,620 +38.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 130508442651 +47.3%
Cash from Investing Activity -896-326-677-512 +24.4%
Cash from Financing Activity 333-66288-83 -128.8%
Net Cash Flow -4331155256 +7.7%
Free Cash Flow 111497412606 +47.1%
CFO/OP 60%125%110%129% +17.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 102919780 -17.5%
Cash Conversion Cycle 102919780 -17.5%
Working Capital Days 412739120 +207.7%
ROCE % 33%29%25%19% -24.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
FIIs 10.04%11.30%11.48%10.27% -10.5%
DIIs 7.20%6.95%8.06%8.29% +2.9%
Public 82.75%81.74%80.44%81.43% +1.2%
No. of Shareholders 1,51,9971,51,8091,47,1821,42,119 -3.4%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Indegene Limited's revenue in Q1 FY27?
Indegene Limited reported revenue of ₹1,063 crore for the quarter ended June 2026 (Q1 FY27), up 39.7% from ₹761 crore in the same quarter last year, and up 6.0% sequentially over the March 2026 quarter.
What was Indegene Limited's net profit in Q1 FY27?
Net profit fell 0.2% year-on-year to ₹116 crore, from ₹116 crore. Earnings per share (EPS) came in at ₹4.84.
What is INDGN's market capitalisation and P/E ratio?
At the current price of ₹598.30, INDGN has a market capitalisation of ₹14,408 crore and a trailing P/E of about 35.9.
Who owns Indegene Limited? (shareholding pattern)
As of Mar 2026, foreign institutional investors (FIIs) 10.27%, domestic institutional investors (DIIs) 8.29%, public shareholders 81.43% of Indegene Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI